Natco Pharma Limited has informed the Exchange regarding a press release dated February 05, 2021, titled "NATCO receives approval for Chlorantraniliprole (CTPR)- 1st key product of Crop Health Sciences Division".
Press Release Feb 05 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This approval was granted by the Central Insecticide Board & Registration Committee, making NATCO the first indigenous manufacturer of this product. Chlorantraniliprole is used in broad-spectrum insecticides for pest management in various crops, and NATCO plans to make it accessible to farmers in India. The company also notes a pending litigation against FMC regarding the use of Chlorantraniliprole.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from NATCO Pharma
- NATCO Pharma launches anti blood clot tablet Rivaroxaban in India
- Press Release Dec 17 2020
- NATCO Pharma receives Pomalidomide approval for US market
- Press Release Nov 13 2020
- Press Release Nov 12 2020
Later from NATCO Pharma
- NATCO Pharma receives approval for Chlorantraniliprole 1st key product of Crop Health Sciences Division
- Press Release Feb 26 2021
- NATCO Pharma launches Brivaracetam tablets, in India, for treatment of epilepsy
- Press Release Mar 08 2021
- Press Release Mar 15 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma